The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFOX4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
M. Guan
No relevant relationships to disclose
C. Bai
No relevant relationships to disclose
S. Chen
No relevant relationships to disclose
H. Ying
No relevant relationships to disclose
X. Li
No relevant relationships to disclose
J. Zhou
No relevant relationships to disclose
Y. Shao
No relevant relationships to disclose
Y. Lin
No relevant relationships to disclose
X. Yang
No relevant relationships to disclose